相关实验视频

Updated: May 5, 2026

Semi-Targeted Ultra-High-Performance Chromatography Coupled to Mass Spectrometry Analysis of Phenolic Metabolites in Plasma of Elderly Adults

Semi-Targeted Ultra-High-Performance Chromatography Coupled to Mass Spectrometry Analysis of Phenolic Metabolites in Plasma of Elderly Adults

Published on: April 22, 2022

艺术菌毛细菌的潜在益生菌作用 - - 由转糖基化产品衍生的转糖基化产品

Heewon Moon¹, Keunsoo Kang², Misook Kim¹

¹Department of Food Science and Nutrition, Dankook University, Cheonan 31116, Republic of Korea.

Foods (Basel, Switzerland)

|October 26, 2024

概括

一种新型的转糖基化产品 (ACOD) 促进有益的肠道细菌并抑制病原体. ACOD显著增强短链脂肪酸,表明其作为改善肠道健康的益生菌的潜力.

科学领域:

微生物学微生物学
肠道微生物群研究研究
生物技术是生物技术.

背景情况:

肠道微生物群在宿主健康中起着至关重要的作用.
益生菌是不可消化的食品成分,通过选择性地刺激结肠中的一种或有限数量的细菌的生长和/或活动,对宿主产生有益影响.
开发具有增强疗效的新型益生菌是一种正在进行的研究领域.

研究的目的:

为了研究由德克斯转糖酶衍生的转糖酶化产品 (ACOD) 的益生菌潜力.
通过便发酵评估ACOD对肠道微生物群组成和功能的影响.
为了比较 ACOD 与果醇糖 (FOS) 的作用.

主要方法:

通过使用Leuconostoc mesenteroides MKSR dextransucrase,糖糖,麦芽糖和Artemisia capillaris合成了ACOD.
进行了体外测试,以评估ACOD对特定益生菌和致病细菌生长的影响.
便发酵进行了24小时,以分析短链脂肪酸 (SCFA) 生产和微生物群组成变化.

主要成果:

ACOD选择性地促进了有益细菌 (例如,Lactiplantibacillus plantarum,Lacticaseibacillus casei) 的生长,同时抑制了致病细菌 (例如,大肠杆菌,Listeria monocytogenes).
ACOD显著增加了SCFA的产量,包括酸 (与FOS相比增加4.5倍) 和酸 (与FOS相比增加3.3倍).
通过增加Lactobacillus丰富度和减少Escherichia/Shigella和沙门氏菌,ACOD调节了肠道微生物群组成,与促进沙门氏菌生长的FOS不同.

结论:

由于其调节肠道微生物群组成并增强SCFA生产的能力,ACOD显示出显著的益生菌潜力.
ACOD作为有益细菌的基质,有助于更健康的肠道环境.
ACOD代表了一个有前途的替代品或补充现有的益生菌,如FOS.

关键词:

牛乳杆菌 (Lactobacillus) 是一种细菌.沙门氏菌是一种沙门氏菌.我们的肠道微生物群.在体外发酵发酵.益生菌益生菌前生物转糖基化产品的转糖基化产品.

更多相关视频

Screening and Isolation of C-Glycoside-Cleaving Intestinal Bacteria

Screening and Isolation of C-Glycoside-Cleaving Intestinal Bacteria

Published on: February 28, 2025

Structural Biology and Analytical Chemistry Approaches for Characterizing C-Glycoside Metabolic Enzymes in Human Gut Microbiota

Structural Biology and Analytical Chemistry Approaches for Characterizing C-Glycoside Metabolic Enzymes in Human Gut Microbiota

Published on: May 23, 2025

相关概念视频

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

Probiotics

Probiotics

Probiotics are live, non-pathogenic microorganisms that confer health benefits by modulating the gut microbiota. The human gastrointestinal tract harbors a complex microbial ecosystem, and the balance of this microbiota is crucial for digestive and systemic health. Among the most extensively studied and utilized probiotics are species formerly classified within the genera Lactobacillus and Bifidobacterium. These organisms not only naturally colonize the human gut but are also consumed through...